Roche: leukemia drug shows 'meaningful' improvements

(CercleFinance.com) - New data confirm that Roche's antibody Gazyva/Gazyvaro extends the lives of people with chronic lymphocytic leukaemia compared to MabThera/Rituxan, another of Roche's drugs, the Swiss drugmaker said on Friday.


After a follow-up of nearly five years, final results of a phase III trial involving 800 people showed clinically meaningful improvements with Gazyva/Gazyvaro plus chlorambucil across multiple endpoints, including progression-free survival and overall survival, Roche said.

Gazyva/Gazyvaro reduced the risk of death by 24% compared to MabThera/Rituxan, the biopharma group said.

In detail, the majority of patients treated with Gazyva/Gazyvaro are still alive after nearly five years of treatment, Roche added.

Gazyva/Gazyvaro is currently approved in over 90 countries for people with previously untreated chronic lymphocytic leukemia, the most common form of the disease.

Copyright (c) 2018 CercleFinance.com. All rights reserved.